1.上海市浦东新区中医医院(上海 201200)
2.上海中医药大学中医脾胃病研究所(上海 200032)
扫 描 看 全 文
李瑗,陆璐,胡宗德等.基于网络药理学及实验验证探讨白头翁汤抗结直肠腺瘤的作用机制[J].上海中医药大学学报,2023,37(04):47-58.
LI Yuan,LU Lu,HU Zongde,et al.Exploration on mechanism of Baitouweng Decoction against colorectal adenoma based on network pharmacology and experimental validation[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(04):47-58.
李瑗,陆璐,胡宗德等.基于网络药理学及实验验证探讨白头翁汤抗结直肠腺瘤的作用机制[J].上海中医药大学学报,2023,37(04):47-58. DOI: 10.16306/j.1008-861x.2023.04.006.
LI Yuan,LU Lu,HU Zongde,et al.Exploration on mechanism of Baitouweng Decoction against colorectal adenoma based on network pharmacology and experimental validation[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(04):47-58. DOI: 10.16306/j.1008-861x.2023.04.006.
目的,2,基于网络药理学分析及实验验证探讨白头翁汤抗结直肠腺瘤的作用机制。,方法,2,利用Cytoscape 3.9.0软件、中药系统药理学数据库与分析平台(TCMSP)、GeneCards数据库等构建“疾病-药物化学成分-靶点”网络,推测白头翁汤治疗结直肠腺瘤的有效化学成分,并进行基因本体(GO)功能富集和京都基因与基因组百科全书(KEGG)通路富集分析,构建“信号通路-靶点”网络,推测核心靶点。最后通过小鼠结直肠腺瘤模型对预测出的核心靶点进行验证。,结果,2,①通过网络药理学分析筛选获得白头翁汤活性成分治疗结直肠腺瘤的潜在靶点129个,其中10种活性成分对应40个关键潜在效应靶点。白头翁汤可能通过调节白介素-17(IL-17)信号通路、p53信号通路来影响DNA结合转录因子的结合、DNA聚合酶Ⅱ型特异性DNA结合转录因子的结合、核因子受体活性等生物学过程,对结直肠腺瘤起到治疗作用。②对12个超过度值均值的靶点进行实验验证,结果显示白头翁汤干预后雌激素受体1(,ESR1,)与半胱天冬酶8(,CASP8,)基因表达较模型组显著降低(,P,<,0.05),推测其为白头翁汤治疗结直肠腺瘤的关键靶点。,结论,2,白头翁汤可能通过多成分、多靶点、多途径的方式发挥抗结直肠腺瘤的作用。
Objective: To explore the mechanism of Baitouweng Decoction against colorectal adenoma based on network pharmacology analysis and experimental verification.,Methods,2,Cytoscape 3.9.0 software, Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and GeneCards database were used to construct a “disease-drug chemical component-target” network to predict the effective chemical components of Baitouweng Decoction in the treatment of colorectal adenoma. Gene Ontology(GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis were carried out to construct a “signal pathway-target” network and predict the core targets. Finally, the predicted core targets were validated in a mouse colorectal adenoma model.,Results,2,①The network pharmacological analysis showed that there are 129 potential targets of Baitouweng Decoction active ingredients in the treatment of colorectal adenoma, among which 10 active ingredients were corresponding to 40 key potential targets. And Baitouweng Decoction may exert therapeutic effects on colorectal adenoma by regulating the interleukin-17 (IL-17) signaling pathway and p53 signaling pathway to affect biological processes such as the DNA-binding transcription factor binding, DNA polymerase type Ⅱ specific DNA-binding transcription factor binding, nuclear factor receptor activity. ②Experimental validation was carried out on 12 targets that exceeded the mean value of degree values, and the results showed that the expression of estrogen receptor 1 (,ESR1,) and caspase-8 (,CASP8,) genes after the intervention of Baitouweng Decoction was significantly decreased compared with that of the model group (,P,<,0.05), which is presumed to be the key targets of Baitouweng Decoction in the treatment of colorectal adenoma.,Conclusion,2,Baitouweng Decoction may exert anti-colorectal adenoma effect through multiple components, multiple targets and multiple pathways.
白头翁汤结直肠腺瘤网络药理学IL-17信号通路p53信号通路ESR1CASP8
Baitouweng Decoctioncolorectal adenomanetwork pharmacologyIL-17 signaling pathwayp53 signaling pathwayESR1CASP8
谢子葳,李鑫,谢碧岑,等. 白头翁汤调控细胞因子治疗溃疡性结肠炎作用机制研究进展[J]. 中成药,2021, 43(8): 2145-2148.
XIE Z W, LI X, XIE B C,et al. Research advances in the mechanism of action of Baitouweng Tang regulating cytokines in the treatment of ulcerative colitis[J]. Traditional Chinese Patent Medicine, 2021, 43(8): 2145-2148.
杨昌文. 白头翁汤及拆方对模型小鼠抗炎作用的实验研究[J]. 中国中医急症,2016, 25(9): 1737-1739.
YANG C W. Experimental study on the anti-inflammatory effect of Baitouweng Tang and its dismantled formula on model mice[J]. Journal of Emergency in Traditional Chinese Medicine, 2016, 25(9): 1737-1739.
胡正国,陈冬,庞德湘. 庞德湘教授运用经方白头翁汤加减治疗直肠癌经验[J]. 黑龙江中医药,2015, 44(6): 30-31.
HU Z G,CHENG D,PANG D X. Professor Pang Dexiang's experience in treating rectal cancer using the Sutra formula Bai Tou Weng Tang with addition and reduction[J]. Heilongjiang Journal of Traditional Chinese Medicine, 2015, 44(6): 30-31.
唐蔚,宋程. 蒋益兰治疗大肠癌经验[J]. 湖南中医杂志,2014,30(12): 25-26.
TANG W,SONG C. Jiang Yilan's experience in treating colorectal cancer[J]. Hunan Journal of Traditional Chinese Medicine, 2014, 30(12): 25-26.
张保国,梁晓夏,刘庆芳. 白头翁汤现代药效学研究[J]. 中成药,2009, 31(4): 607-608.
ZHANG B G, LIANG X X,LIU Q F. A modern pharmacodynamic study on the efficacy of Bai Tou Weng Tang[J]. Traditional Chinese Patent Medicine, 2009, 31(4): 607-608.
陈凯,张文明,喻凯,等. 白头翁中抗肿瘤物质的筛选及其作用机制研究[J]. 天然产物研究与开发,2016, 28(12): 1875-1879.
CHEN K,ZHANG W M,YU K,et al. Screening of Antitumor Compounds from Radix Pulsatillae and Researching on Their Mechanism[J]. Natural Product Research and Development, 2016, 28(12): 1875-1879.
SHI X,YANG Z,WU Q,et al. Colorectal adenoma recurrence rates among post-polypectomy patients in the placebo-controlled groups of randomized clinical trials: a meta-analysis[J]. Oncotarget, 2011, 8(37): 62371-62381.
FACCIORUSSO A, DI MASO M, SERVIDDIO G, et al. Development and validation of a risk score for advanced colorectal adenoma recurrence after endoscopic resection[J]. World J Gastro-enterol, 2016, 22(26): 6049-6056.
程怡,张北平. 基于“Wnt/β-catenin信号通路-伏毒致病”论述结直肠腺瘤病因病机[J]. 中医学报,2021, 36(6): 1203-1206.
CHENG Y, ZHANG B P. Discussion on Etiology and Pathogenesis of Colorectal Adenoma from Perspective of Wnt/β-Catenin Signaling Pathway-Toxin Causing Theory[J]. Acta Chinese Medicine, 2021, 36(6): 1203-1206.
乌日嘎,宋晓彪,梁永贵,等. 结直肠腺瘤发病影响因素的研究进展[J]. 中国普通外科杂志,2021, 30(10): 1235-1244.
WU R G, SONG X B,LIANG Y G, et al. Research progress on influencing factors for the pathogenesis of colorectal adenoma[J]. Chinese Journal of General Surgery, 2021, 30(10): 1235-1244.
蒋文贤,陈培富. 慢性炎症与癌症关系研究进展[J]. 动物医学进展,2019, 40(3): 114-118.
JIANG W X,CHEN P F. Advances in research on the relationship between chronic inflammation and cancer[J]. Progress in Veterinary Medicine, 2019, 40(3): 114-118.
谷文超,陈聪,宋咏梅,等. 网络药理学在中医复方研究中的应用现状[J]. 山东中医杂志,2021, 40(6): 662-667.
GU W C, CHEN C, SONG Y M,et al. Application of Network Pharmacology in Studying Formulas of Traditional Chinese Medicine[J]. Shandong Journal of Traditional Chinese Medicine,2021, 40(6): 662-667.
王凤雪,高宇,刘海波. 中药网络药理学研究流程及代表性数据库工具[J]. 中国现代中药,2021, 23(6): 1111-1118.
WANG F X, GAO Y, LIU H B. Research Process and Representative Database Tools of Traditional Chinese Medicine Network Pharmacology[J]. Modern Chinese Medicine, 2021, 23(6): 1111-1118.
刘鑫馗,吴嘉瑞,蔺梦娟,等. 基于网络药理学的四君子汤作用机制分析[J]. 中国实验方剂学杂志,2017, 23(16): 194-202.
LIU X K,WU J R,LIN M J, et al. Chinese Journal of Experimental Traditional Medical[J]. Chinese Journal of Experimental Traditional Medical, 2017, 23(16): 194-202.
曾紫凡,任莹璐,王勇,等. 基于网络药理学预测丹参干预心力衰竭的作用机制研究[J]. 中西医结合心脑血管病杂志,2018, 16(10): 1353-1358.
ZENG Z F, REN Y L, WANG Y, et al. Study on the Mechanism of Salvia Miltiorrhiza in the Treatment of Heart Failure Predicted by Network Pharmacology[J]. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease,2018,16(10):1353-1358.
王子怡,王鑫,张岱岩,等. 中医药网络药理学:《指南》引领下的新时代发展[J]. 中国中药杂志,2022, 47(1): 7-17.
WANG Z Y, WANG X, ZHANG D Y, et al. Traditional Chinese medicine network pharmacology:development in new era under guidance of network pharmacology evaluation method guidance[J]. China Journal of Chinese Materia Medica, 2022, 47(1): 7-17.
BATEMAN A,PEARSON W R, STEIN L D ,et al. Using DrugBank for In Silico Drug Exploration and Discovery[J]. Curr Protoc Bioinformatics, 2002, 14(4): 1-31.
WISHART D S, FEUNANG Y D, GUO A C, et al. DrugBank 5.0: a major update to the DrugBank database for 2018[J]. Nucleic Acids Res, 2018, 46(D1): D1074-D1082.
XU X, ZHANG W,HUANG C, et al. A Novel Chemometric Method for the Prediction of Human Oral Bioavailability[J]. Int J Mol Sci, 2012: 6964-6982.
SHANNON P,MARKIEL A,OZIER O,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
DONCHEVA N T, MORRIS J H, GORODKIN J, et al. Cytoscape string App: Network analysis and visualization of proteomics data[J]. J Proteome Res, 2019, 18(2): 623-632.
LIANG W, PENG X,LI Q, et al. FAM3D is essential for colon homeostasis and host defense against inflammation associated carcinogenesis[J]. Nat Commun, 2020, 11(1): 5912.
CHAKRADHAR S. Colorectal cancer: 5 big questions[J]. Nature. 2015, 521(7551): S16.
徐叔云, 卞如濂,陈修. 药理实验方法学(第三版)[M]. 北京:人民卫生出版社,2005: 202-203.
XU S Y, BIAN R L, CHEN X. Pharmacological Laboratory Methodology (3rd Edition)[M]. Beijing: People's Health Publishing House, 2005: 202-203.
吴静怡,曹海龙,王邦茂. 重视结直肠腺瘤癌变的精准防治[J]. 中国实用内科杂志,2018, 38(9): 784-787.
WU J Y,CAO H L,WANG B M. Pay attention to precise prevention and treatment of colorectal adenoma carcinogens[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9):784-787.
张北平,魏玮,李爱民,等. 结直肠腺瘤及早期结直肠癌中西医结合诊治专家共识(2021)[J]. 中医杂志,2022, 63(10): 989-997.
ZHANG B P,WEI W,LI A M,et al. Integrating Chinese and Western Medicine in Colorectal Adenoma and Early Colorectal Cancer Expert Consensus on Diagnosis and Treatment (2021) [J]. Journal of Traditional Chinese Medicine,2022,63(10):989-997.
刘佳,郭文洁,耿骥,等. 异鼠李素诱导HCT116细胞自噬[J]. 中成药,2015, 37(12): 2596-2599.
LIU J, GUO W J, GENG J, et al. Isorhamnetin induces autophagy in HCT116 cells[J]. Chinese Traditional Patent Medicine, 2015, 37(12): 2596-2599.
王伟强,李晓,陈玉华,等. 黄连素对结直肠腺瘤内镜下切除后复发的预防作用[J]. 胃肠病学和肝病学杂志,2020, 29(1): 46-49.
WANG W Q,LI X,CHEN Y H,et al. Preventive effects of Berberine in the recurrence of colorectal adenoma after endoscopic resection[J]. Chinese Journal of Gastroenterology and Hepatology, 2020, 29(1): 46-49.
ONISHI R M,GAFFEN S L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease[J]. Immunology, 2010, 129(3): 311-321.
CUI G,YANG H,ZHAO J,et al. Elevated Proinflammatory Cytokine IL-17A in the Adjacent Tissues Along the Adenoma-Carcinoma Sequence[J]. Pathol Oncol Res,2015,21(1):139-146.
CUI G, LI Z, FLORHOLMEN J, et al. Dynamic stromal cellular reaction throughout human colorectal adenoma-carcinoma sequence: A role of TH17/IL-17A[J]. Biomed Pharmacother,2021, 140: 111761.
CHEN J,YE X,PITMON E,et al. IL-17 inhibits CXCL9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors[J]. J Immunother Cancer,2019,7(1): 324.
FENG H, YING R, CHAI T, et al. The association between IL-17 gene variants and risk of colorectal cancer in a Chinese population: A case⁃control study[J]. Biosci Rep, 2019, 39(11): BSR20190013.
MENG F, WANG K, AOYAMA T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice[J]. Gastroenterology,2012, 143(3): 765-776.
节阳华,杨晓蓓,陈卫东. 白头翁汤对结直肠癌小鼠炎性微环境的影响[J]. 广州中医药大学学报,2020, 37(12): 2406-2412.
JIE Y H,YANG X B,CHEN W D. Effects of Baitouweng Decoction on Inflammatory Microenvironment in Mice with Colorectal Cancer[J]. Journal of Guangzhou University of Traditional Chinese Medicine, 2020, 37(12): 2406-2412.
KANDOTH C, MCLELLAN M D, VANDIN F, et al. Mutational landscape and significance across 12 major cancer types[J]. Nature, 2013, 502(7471): 333-339.
JORUIZ S M,BOURDON J C. p53 Isoforms: Key Regulators of the Cell Fate Decision[J]. Cold Spring Harb Perspect Med, 2016, 6(8): a026039.
KANAPATHIPILLAI M. Treating p53 Mutant Aggregation-Associated Cancer[J]. Cancers (Basel), 2018, 10(6): 154.
LIEBL M C, HOFMANN T G. The Role of p53 Signaling in Colorectal Cancer[J]. Cancers (Basel), 2021, 13(9): 2125.
SABAPATHY K,LANE D P. Therapeutic targeting of p53: all mutants are equal,but some mutants are more equal than others[J]. Nat Rev Clin Oncol, 2018, 15(1): 13-30.
RUBIO CA, RODESJÖ M, DUVANDER A, et al. p53 up-regulation during colorectal carcinogenesis[J]. Anticancer Res, 2014, 34(12): 6973-6979.
NOGUEIRA R B,PIRES A R,SOARES T M,et al. Immuno-expression of the COX-2, p53,and caspase-3 proteins in colorectal adenoma and non-neoplastic mucosa[J]. Einstein (Sao Paulo), 2013, 11(4): 456-461.
RUSSO A, BAZAN V, IACOPETTA B,et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site,type of mutation,and adjuvant treatment[J]. J Clin Oncol, 2005, 23(30): 7518-7528.
DI AGOSTINO S, STRANO S, EMILIOZZI V,et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation[J]. Cancer Cell, 2006, 10(3): 191-202.
ALEXANDROVA E M, YALLOWITZ A R, LI D,et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment[J]. Nature, 2015, 523(7560): 352-356.
PAUN B C, KUKURUGA D,JIN Z,et al. Relation between normal rectal methylation, smoking status,and the presence or absence of colorectal adenomas[J]. Cancer, 2010,116(19):4495-4501.
RAWUSZKO-WIECZOREK A, MARCZAK U, HORST N, et al. Significance of intratissue estrogen concentration coupled with estrogen receptors levels in colorectal cancer prognosis[J]. Oncotarget, 2017, 8(70): 115546-115560.
FRITSCH M, GÜNTHER S D, SCHWARZER R, et al. Caspase-8 is the molecular switch for apoptosis,necroptosis and pyroptosis[J]. Nature, 2020, 575(7784): 683-687.
UZUNPARMAK B, GAO M, LINDEMANN A, et al. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic induced necroptosis[J]. JCI Insight, 2020, 5(23): e139837.
SUN T, GAO Y, TAN W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers[J]. Nat Genet, 2007, 39(5): 605-613.
PITTMAN A M, BRODERICK P, SULLIVAN K, et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population[J]. Br J Cancer, 2008, 98(8): 1434-1436.
SHI J, WANG L, YIN X, et al. Comprehensive characterization of clonality of driver genes revealing their clinical relevance in colorectal cancer[J]. J Transl Med, 2022, 20(1): 362.
0
Views
98
下载量
0
CSCD
0
CNKI被引量
Publicity Resources
Related Articles
Related Author
Related Institution